Lyra Therapeutics Halts Drug Development, Cuts Entire Workforce
Lyra Therapeutics suspends LYR-210 development for chronic rhinosinusitis, lays off 28 employees, and explores strategic alternatives as stock plummets 44% in premarket trading.
/ 1 item
#LYRA↓